Saran Jonas

Biosketch / Results /

Saran Jonas

Clinical Professor, Department of Neurology
Professor Emeritus of Neurology, Department of Neurology

Dir of EEG Laboratory at BHC
Assoc Dir of Neurology at BHC

Contact Info

Address
462 First Avenue
New York, NY 10016

212/263-7591
Saran.Jonas@nyumc.org

Education

1952-1956 — Columbia University, College of Physicians and Surgeons, Medical Education
1956 — Columbia University College of Physicians & Surgeons, Medical Education
1956-1957 — Bellevue Hospital Center, Internship
1956-1957 — Bellevue Hospital Center (Medicine), Internship
1957-1962 — Bellevue Hospital Center (Medicine & Neurology), Residency Training

Research Summary

Saran Jonas, M.D. and a multidisciplinary team of investigators are engaged in studies to prevent and treat stroke. At NYUMC/BHC the Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events (CAPRIE) is comparing a new antiplatelet agent, clopidogrel, to conventional therapy with aspirin in the prevention of recurrent stroke. Eligible patients are randomized within six months of ischemic stroke onset. The NASCET (North American Symptomatic Carotid Endartetectomy Trial) study at NYUMC/BH is random for endarterectomy or medical management within 3 months of event. TIA-minor stroke patients with 30-69% relevant carotid stenosis. The WARSS trial (Warfarin Aspirin Recurrent Stroke Study) at the New York Department of Veterans Affairs Medical Center compares the efficacy of aspirin and warfarin in stroke prevention. Eligible veterans must be enrolled within 30 days of ischemic stroke onset. Also at the New York VAMC, investigators are carrying out a study to refine the recognition of the effects (neuropsychological and other) of cerebral microemboli during cardiac surgery, in order to enhance the ability to use this situation to test neuroprotective drugs.

At Tisch Hospital the use of intra-arterial thrombolytic agents for the treatment of acute stroke is being evaluated in conjunction with the Department of Radiology. Eligible patients are assessed and treated as soon as possible within the first few hours of ischemic stroke symptoms. Two potential neuroprotective agents, lubelozole and eloprodil are also being tested and administered to patients within the first 6 hours of stroke onset.

Research Interests

Prevention and Treatment of Stroke

Serum Taurine and Stroke Risk in Women: A Prospective, Nested Case-Control Study
Wu, Fen; Koenig, Karen L; Zeleniuch-Jacquotte, Anne; Jonas, Saran; Afanasyeva, Yelena; Wojcik, Oktawia P; Costa, Max; Chen, Yu. Serum Taurine and Stroke Risk in Women: A Prospective, Nested Case-Control Study. PLoS one. 2016 Feb 11;11(2):e0149348-e0149348 e0149348 (1948722)

Mortality, ethnicity, and education in an occupational cohort
Jonas, Saran; Grieco, Giacinto; Norman, Robert; Grumet, Surah; Kedan, Ilan. Mortality, ethnicity, and education in an occupational cohort. Ethnicity & inequalities in health & social care. 2014 ;7(3):137-145 (1422422)

Neuroprotection by inhaled nitric oxide in a murine stroke model is concentration and duration dependent
Li, Yong-Sheng; Shemmer, Benjamin; Stone, Eric; A Nardi, Michael; Jonas, Saran; Quartermain, David. Neuroprotection by inhaled nitric oxide in a murine stroke model is concentration and duration dependent. Brain research. 2013 Mar 5;1507:134-145 (287232)

C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates and protects against carotid artery occlusion and cerebral stroke
Li, Zongdong; Nardi, Michael A; Li, Yong-Sheng; Zhang, Wei; Pan, Ruimin; Dang, Suying; Yee, Herman; Quartermain, David; Jonas, Saran; Karpatkin, Simon. C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates and protects against carotid artery occlusion and cerebral stroke. Blood. 2009 Feb 13;113(24):6051-6060 (93983)

Reply to the letter by Derendorf: Clinical trials and dipyridamole formulation selection
Grieco, G; Jonas, S. Reply to the letter by Derendorf: Clinical trials and dipyridamole formulation selection [Letter]. Cerebrovascular diseases. 2007 FEB ;23(1):73-74 (70340)